December 18, 2013 at 10:49 AM
Topics: ISCO, human induced pluripotent stem cell
December 9, 2013 at 11:54 AM
International Stem Cell Corporation (ISCO:OTCQB), a biotechnology company developing novel stem cell-based therapies, announced the development of a new method for the derivation of human induced pluripotent stem cells (iPS) that utilizes a novel protein-based reprogramming process. The Company believes that the new method is a safer and more efficient alternative to older iPS reprogramming techniques, and represents a step forward in the ability to use iPS clinically.
Topics: ISCO, human induced pluripotent stem cell
November 13, 2013 at 1:37 PM
International Stem Cell Corp. (ISCO-OTCQB), a biotechnology company developing novel stem cell-based therapies and biomedical products, provided a business update and announced financial results for the three and nine months ended September 30, 2013.
October 16, 2013 at 11:53 AM
International Stem Cell Corp. (ISCO-OTCQB) has announced new results from its preclinical Parkinson's disease program. ISCO is developing a novel approach that uses self-renewing human parthenogenetic neural stem cells (hPNSCs), which are derived from the Company’s proprietary histocompatible human pluripotent stem cells, to treat Parkinson’s disease. Parkinson's disease is a progressive disorder of the nervous system that affects four million to six million people worldwide (Source: National Parkinson Foundation). It belongs to a group of motor system disorders that result from the loss of dopamine-producing cells in the brain.
ISCO is currently evaluating its Parkinson's therapy in final preclinical primate studies. Data collected as part of a collaboration with the Sanford Burnham Medical Research Institute, summarized below, was announced at the American Neurological Association's 2013 Annual Meeting in New Orleans.
September 18, 2013 at 5:26 PM
Yesterday, we released a Quarterly Update on International Stem Cell Corporation (ISCO-OTC). This 12-page report is a follow-up to our 72-page and very in-depth Executive Informational Overview® published in August. Full text of the newly issued Update is available here.
ISCO is focused on the therapeutic applications of human parthenogenetic stem cells (hpSCs) to treat diseases of the brain, liver, and the eye. ISCO’s proprietary technology is based on the creation of stem cells through parthenogenesis, a form of asexual reproduction that involves the stimulation of a human oocyte (egg) to start the cell division process without actual fertilization. Since the eggs are not fertilized, no viable human embryo is created nor destroyed for the generation of ISCO’s hpSC lines. The Company believes that these therapeutic stem cells avoid the safety, economic, and ethical concerns inherent with existing stem cell technologies.
August 21, 2013 at 12:07 PM
Earlier today, International Stem Cell Corporation (ISCO-OTC) announced that it has signed a master clinical research agreement with Duke University to conduct clinical trials research in Parkinson's disease using ISCO's innovative neural stem cell product. The research is expected to be coordinated by the Duke Clinical Research Institute (DCRI) and led by Mark Stacy, M.D., vice dean for clinical research, neurology at Duke University School of Medicine and one of the preeminent experts on neurology, having published more than 100 peer-reviewed scientific papers on Parkinson's disease and other movement disorders. The collaboration with DCRI also provides ISCO with access to Duke's clinical expertise in cell therapy clinical trials as well as an extensive patient population, giving the Company an opportunity to evaluate its stem cell therapy in Parkinson's disease.
August 6, 2013 at 11:00 AM
International Stem Cell Corporation (“ISCO” or “the Company”) is a biotechnology company focused on the therapeutic applications of human parthenogenetic stem cells (hpSCs) to treat diseases of the brain, liver, and the eye, as well as on the development and commercialization of cell-based research and cosmetic products.
ISCO’s Novel Stem Cell Technology
ISCO is pioneering the development of a new class of stem cells—known as human parthenogenetic stem cells (hpSCs). The Company believes that these therapeutic stem cells avoid the safety, economic, and ethical concerns inherent with existing stem cell technologies.
ISCO’s core proprietary technology, parthenogenesis, refers to a form of asexual reproduction in which an egg develops without being fertilized by a male gamete. The creation of hpSCs involves the stimulation of a human oocyte (egg) to start the cell division process without actual fertilization. Since the eggs are not fertilized, no viable human embryo is created nor destroyed for the generation of ISCO’s hpSC lines. In addition, according to the Company, the histocompatibility profile of hpSCs makes this the only stem cell platform capable of generating stem cell lines that can immune-match millions of people. The main medical, economic, and ethical benefits of hpSCs are summarized in the Figure below.
The Company’s therapeutic efforts for its hpSCs are concentrated in three markets where cell therapy has been clinically proven, but where there is a shortage of safe cells or tissue:
inherited metabolic liver disease; and
ISCO believes these markets could have a combined revenue potential of over $5 billion. ISCO is also employing its proprietary stem cell technology to develop an stem cell bank, UniStemCell™, which already contains enough histocompatible stem cell lines to immune-match over 75 million people.
Revenue-Generating Therapeutic Programs
The Company produces and markets specialized cells and growth media for therapeutic research through its subsidiary Lifeline Cell Technology (www.lifelinecelltech.com) and SC-based skin care products through its subsidiary Lifeline Skin Care (www.lifelineskincare.com). During 2012, these companies generated approximately $4.6 million in sales.
Business Model and Growth Strategy
ISCO uses its proprietary platform technology to operate under a novel business model for the biotechnology industry (see ISCO'S Business Model below). Specifically, the revenue-generating commercial operations of its subsidiary businesses (Lifeline Cell Technology and Lifeline Skin Care) support the development of the Company’s therapeutic programs and licensing opportunities. This model not only provides practical, short-term applications of the Company’s core technologies, but also generates financial resources to support further scientific research and development of ISCO’s therapeutic programs in Parkinson’s disease, metabolic liver disease, and corneal blindness. In addition, ISCO’s plans include the creation of an SC bank and, once it has proven the technology platform by developing the therapeutic treatments, the licensing of its technologies to third parties for the development of third-party treatments.
Learn More About International Stem Cell Corporation
Crystal Research has published a 72-page Executive Information Overview® on International Stem Cell Corporation, which overviews the Company's products and technologies, as well as its growth strategy, intellectual property, management, competition, among other relevant information. A free copy of the report can be downloaded via ISCO's Corporate Profile.
Follow Crystal Research on LinkedIn, Twitter (@CrystalResearch) or Facebook to be among the first to hear about new published research on ISCO as well as for updates on International Stem Cell Corporation's latest developments.
Topics: ISCO, New Research
We provide investor-based research and corporate communications services to companies worldwide. Visit our About Us page to learn more.